News

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.
Oct 31

Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

NMD4C members gather for a group photo at the annual meeting.
Oct 06

Annual NMD4C Meeting Recap

CNDR logo4x3
Oct 06

National Consensus Meeting to Decide Outcome Measures for Adults with SMA

NMD4C at Ottawa NMD 2023, parliament building in Ottawa in the background.
Oct 06

NMD4C at Ottawa NMD 2023

ImPORTND logo with text reading 'new module - skills for patient oriented research'
Sep 05

New Course ‘Skills for Patient Oriented Research’ Added to ImPORTND Training Platform

MDC, NMD4C and CSCN fellowships competition is now open
Sep 05

Annual Neuromuscular Postdoctoral Research and Clinical Fellowships Funding Competition Now Open

canada-people
Jul 04

Curriculum Group Wraps up Inaugural Fellows’ Training Series

NMD4C and MDC together offer free training and support for research teams and patients to conduct patient oriented research
Jul 04

ImPORTND – Training for Research Teams and Patient and Family Partners to Conduct Patient-Oriented Research in Neuromuscular Diseases

NMD4C awarded grant funding from CIHR-IMHA and funding from MDC for a period of 5 years.
Jun 21

Press Release | Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care